1
Clinical Trials associated with CD-19 CAR-T Cell(Hong Kong Children's Hospital) / RecruitingNot ApplicableIIT Safety and Feasibility Study of CD19 Chimeric Antigen Receptor (CAR) T Cells in Children with Relapsed or Refractory CD19 Positive Acute Lymphoblastic Leukemia or Lymphoma
This study seeks to examine the efficacy and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor (CAR) targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoma. The overall goal of this study is to validate the safety profile of administration CD19-CAR T cells and describe the response rate in children with relapsed/refractory ALL or lymphoma.
100 Clinical Results associated with CD-19 CAR-T Cell(Hong Kong Children's Hospital)
100 Translational Medicine associated with CD-19 CAR-T Cell(Hong Kong Children's Hospital)
100 Patents (Medical) associated with CD-19 CAR-T Cell(Hong Kong Children's Hospital)
100 Deals associated with CD-19 CAR-T Cell(Hong Kong Children's Hospital)